HRMY

Harmony Biosciences Holdings, Inc. operates in the health care sector, within the biotechnology industry, focusing on the development and commercialization of therapies for rare neurological disorders. The company’s shares are traded on the Nasdaq under the ticker HRMY.

Founded by pharmaceutical industry executives with support from biotechnology-focused investors, the company was created to address therapeutic gaps in diseases affecting the central nervous system.

Its main areas of activity include:

• Development of therapies targeting neurological and sleep-related disorders.
• Clinical research and drug development programs for rare diseases.
• Regulatory and scientific support for healthcare professionals.
• Commercialization of specialized treatments in the neuroscience field.

Harmony Biosciences’ commercial activities are primarily concentrated in the United States, while research collaborations with academic institutions and clinical centers support ongoing clinical development programs.

Industry dynamics affecting the company include FDA regulatory policies, drug approval timelines, research and development costs, and competition among biotechnology firms focused on treatments for rare neurological conditions.

The company is headquartered in Plymouth Meeting, Pennsylvania.

History and Development

Harmony Biosciences was founded in 2017 in the United States with the objective of developing therapies for rare neurological diseases.

In its early stages, the company focused on structuring clinical development programs, licensing therapeutic compounds, and advancing research aligned with regulatory requirements.

A key milestone occurred in 2019 with the commercial launch of its lead therapy for narcolepsy. In 2020, the company completed its initial public offering (IPO) on Nasdaq, supporting further development of its clinical pipeline.

In recent years, Harmony Biosciences has continued expanding its research activities, conducting multicenter clinical studies and evaluating additional therapeutic opportunities within neuroscience.

Additional Information

Harmony Biosciences Holdings Inc. (United States) is listed on the Nasdaq and has a market capitalization of $1.58 Billion, with shareholders equity totaling $870.22 Millions.

The company employs approximately 150 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Harmony Biosciences Holdings Inc. reported $868.46 Millions in revenue, generating net income of $158.70 Millions.

Key financial metrics include a P/E ratio of 9.96, a price-to-book (P/B) ratio of 1.82, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker HRMY.